2Pasquali R, Gambineri A. Insulin - sensitizing agents in polycystie ova- ry syndrome [J] . Eur J Endocrinol, 2006, 154 (6): 763.
3Martens JW, Geller DH, Arlt W et al. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syn- drome [J]. Clin Endocrinol Metab, 2000, 85 (11) : 4338.
3Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome : the Rotterdam criteria are premature. J Clin Endocrinol Metab,2006, 91:781-785.
4Azziz R, Carmina C, Dewailly D, et al. Positions statement : criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome : an Androgen Excess Society guideline. J Clin Endocrinol Metab, 2006, 91 : 4237-4245.
5Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome : in defence of the Rotterdam criteria. J Clin Endocrinol Metab, 2006, 91: 786-789.
6Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab, 2005, 90 : 2545-2549.
7Jakubowski L. Genetic aspects of polycystic ovary syndrome. Endokrynol Pol, 2005, 56:285-293.
8H. Aizawa,M. Niimura. Adrenal androgen abnormalities in women with late onset and persistent acne[J] 1993,Archives of Dermatological Research(8):451～455
9P. Schramm,W. Gudat,P. Benes. Circulating androgens in men with acne[J] 1990,Archives of Dermatological Research(7):475～476
